Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: tamiya m. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, Tanii H, Shi MM, Kobayashi K, Horio Y. Hida T, et al. Among authors: tamiya m. Cancer Sci. 2011 Apr;102(4):845-51. doi: 10.1111/j.1349-7006.2010.01839.x. Epub 2011 Feb 8. Cancer Sci. 2011. PMID: 21205086 Free article. Clinical Trial.
Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
Tamiya M, Tamiya A, Nakao K, Asami K, Okishio K, Satomu M, Shiroyama T, Morishita N, Suzuki H, Sasada S, Okamoto N, Okishio K, Kawaguchi T, Kobayashi M, Atagi S, Hirashima T, Kawase I. Tamiya M, et al. Among authors: tamiya a. Anticancer Res. 2012 Aug;32(8):3553-7. Anticancer Res. 2012. PMID: 22843945
Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.
Tamiya A, Tamiya M, Shiroyama T, Kanazu M, Hirooka A, Tsuji T, Morishita N, Asami K, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Hirashima T, Atagi S, Kawase I. Tamiya A, et al. Among authors: tamiya m. Ann Oncol. 2013 Apr;24(4):980-5. doi: 10.1093/annonc/mds544. Epub 2012 Nov 7. Ann Oncol. 2013. PMID: 23136232 Free article.
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T. Tamiya M, et al. Among authors: tamiya a. Med Oncol. 2013;30(3):676. doi: 10.1007/s12032-013-0676-7. Epub 2013 Aug 8. Med Oncol. 2013. PMID: 23925664 Clinical Trial.
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Tamiya A, Tamiya M, Shiroyama T, Saijo N, Nakatani T, Minomo S, Tsuji T, Takeuchi N, Omachi N, Kurata K, Suzuki H, Okamoto N, Okishio K, Hirashima T, Atagi S. Tamiya A, et al. Among authors: tamiya m. Med Oncol. 2015 Mar;32(3):40. doi: 10.1007/s12032-014-0474-x. Epub 2015 Jan 25. Med Oncol. 2015. PMID: 25616723 Clinical Trial.
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Tamiya M, et al. Among authors: tamiya a. Med Oncol. 2016 Jan;33(1):2. doi: 10.1007/s12032-015-0715-7. Epub 2015 Nov 24. Med Oncol. 2016. PMID: 26603297 Clinical Trial.
Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan.
Asami K, Kawahara M, Hirashima T, Suzuki H, Okishio K, Omachi N, Tamiya M, Tamiya A, Hirooka A, Nakao K, Tsuji T, Atagi S. Asami K, et al. Among authors: tamiya a, tamiya m. Thorac Cancer. 2014 Jul;5(4):289-96. doi: 10.1111/1759-7714.12091. Epub 2014 Jul 3. Thorac Cancer. 2014. PMID: 26767015 Free PMC article.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T. Tamiya M, et al. Among authors: tamiya a. Anticancer Res. 2016 Jun;36(6):2939-44. Anticancer Res. 2016. PMID: 27272808
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y, Minami S, Futami S, Koba T, Higashiguchi M, Tamiya M, Suzuki H, Hirashima T, Komuta K, Kijima T. Nishijima-Futami Y, et al. Among authors: tamiya m. Cancer Chemother Pharmacol. 2017 Jun;79(6):1215-1220. doi: 10.1007/s00280-017-3321-x. Epub 2017 Apr 28. Cancer Chemother Pharmacol. 2017. PMID: 28455584 Clinical Trial.
182 results